Results 131 to 140 of about 771,765 (294)

Transcranial direct current stimulation targeting the bilateral IFG alters cognitive processes during creative ideation

open access: yesnpj Science of Learning
This study investigated whether transcranial direct current stimulation (tDCS) targeting the inferior frontal gyrus (IFG) can alter the thinking process and neural basis of creativity.
Cong Xie   +3 more
doaj   +1 more source

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte   +10 more
wiley   +1 more source

¿Crisis, qué crisis?

open access: yesrevista PH, 2013
"...Por tanto, mi axioma será justamente ese, que el patrimonio “se dice” (como el “ser” aristotélico) de muchas maneras, una de ellas es la económica.  ¿Es esta faceta económica la más relevante? Esta es la cuestión, maximizada por los tiempos que corren. Pero, en mi opinión, tal emergencia histórica carece de sentido.
openaire   +3 more sources

Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia

open access: yesMolecular Oncology, EarlyView.
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song   +11 more
wiley   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

open access: yesMolecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy